Articles tagged with Melanoma
A new patient-centered approach identifies melanoma patients most likely to benefit from sentinel lymph node biopsy, offering a more accurate and cost-effective method for selecting patients. The study found that adopting a 10% cutoff for positivity rates could help identify patients best eligible for the procedure.
The USPSTF finds the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer. Skin cancer is the most commonly diagnosed cancer in the U.S., with melanomas causing the most skin cancer deaths.
A recent study found that immunotherapy alone resulted in a 89% favorable treatment response rate for patients with desmoplastic melanoma. This suggests that combination therapies may not be necessary for these patients, reducing the risk of toxicity.
A recent clinical trial found that nearly 90% of patients with unresectable desmoplastic melanoma responded to treatment with pembrolizumab. The immunotherapy drug showed impressive results in both treatable and inoperable cases, suggesting a promising treatment option for this rare form of skin cancer.
A new vaccine type, mRNA-4157/V940, added to immunotherapy significantly reduced melanoma recurrence and death rates. The combination was found to be effective in 22.4% of patients compared to 40% without the vaccine.
A study published in Cancer Cell found that prior treatments, such as CTLA-4 blockade, modify the response to anti-PD-1 checkpoint blockade therapy. The research analyzed data from over 500 patients and identified key factors associated with treatment response. This finding may help scientists create more precise future treatments.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
Researchers analyzed autopsies of 14 patients with advanced melanoma, finding that changes to tumor DNA can cause resistance to treatment. The study sheds light on the final stages of cancer and may lead to new treatments for patients with advanced disease.
Scientists have developed a new vaccine delivery method using powdered vaccines and a system driven by compressed gas, called MOF-Jet. The device can deliver therapeutics against cancer and other diseases in a relatively painless way, eliminating the need for needles and potentially reducing pain.
Researchers at Moffitt Cancer Center have discovered a combination strategy that targets the STING signaling pathway, resulting in improved antitumor activity. Inhibiting methylation increases STING expression and activates immune cells, leading to enhanced antitumor immunity.
Researchers from China have identified inosine as a potential broad-spectrum anti-inflammatory agent that improves survival in mice infected with SARS-CoV-2. The study also highlights TBK1 as a promising target for inhibiting cytokine storms and mitigating acute inflammatory lung injury.
A new surgical therapy has proven effective in treating melanoma in the eye that has spread to the liver, with 40% of patients experiencing tumor shrinkage, and offers a promising alternative to current treatments.
A study found that individuals with a history of atopic diseases, such as allergic asthma or rhinitis, had significantly lower rates of melanoma and skin cancer compared to non-atopic individuals. The risk of melanoma was up to 50% lower in atopic patients, and the overall risk of skin cancer was also reduced.
A phase 2 clinical trial shows that treating resectable stage 3 and 4 melanoma patients with pembrolizumab both before and after surgery greatly improves outcomes compared to pembrolizumab given only after surgery. This approach resulted in significantly longer event-free survival rates.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
Researchers found that adding immunotherapy before surgical removal of stage III-IV melanoma significantly improved event-free survival compared to standard-of-care treatment. The study showed that neoadjuvant therapy is superior to the same therapy given in the adjuvant setting.
Researchers found that combining a chemical blocker of immune cell exit with immunotherapy stopped melanoma tumor enlargement in over half of mice tested. The study showed that T cells circulate out of tumors, reshaping scientific views of tumor immunology.
Researchers have discovered that cancer patients who don't respond to immunotherapy often lack CD5+ dendritic cells, which are essential for effective T cell activity. Boosting these cells may help more patients benefit from immunotherapy.
A study by University of Gothenburg researchers found a significant association between methotrexate use and an increased risk of basal cell carcinoma, squamous cell carcinoma, and cutaneous malignant melanoma. The study suggests that higher doses of methotrexate may increase the risk of SCC and BCC, while no dose-response relationship...
Researchers at the University of South Australia are developing new biomarkers to improve melanoma detection and avoid delayed treatment. The current markers used in clinical practice are not always sensitive or specific, leading to fatal consequences if cancerous cells are missed.
Researchers identified a subset of mutations within tumor mutation burden that remain persistent and visible to the immune system, increasing likelihood of response to immunotherapy. This finding enables clinicians to more accurately select patients for clinical trials or predict clinical outcomes with immune checkpoint blockade.
Moffitt researchers found that administering oral L-fucose increases TILs, reduces tumor growth, and enhances immunotherapy efficacy in animal models. Higher L-fucose levels in melanomas are associated with less aggressive disease and better responses to therapy.
Researchers discovered that 15-deoxy-prostamide-J2 induces ER stress-mediated apoptosis selectively in tumor cells, reducing melanoma growth. The molecule activates PERK, IP3R, and the mitochondrial permeability transition pore, leading to cell death.
A new classification system, MPATH-Dx Version 2.0, has been developed to simplify diagnoses of melanocytic skin lesions. The system categorizes lesions into four classes, providing guidance on treatment and surveillance for patients.
A new study found that COVID-19 primarily affected patients with a moderate to critical course, often with comorbidities, whereas many had mild courses despite metastatic melanoma and systemic therapy, recommending continued treatment whenever possible.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Regular use of vitamin D supplements was associated with a significantly reduced risk of melanoma and better skin cancer classification compared to non-users. However, the study did not find a significant association between vitamin D use and other skin changes or severity of photoaging.
A new study has identified a protein called LAP1 that makes melanoma cells more aggressive by changing their nucleus shape. The protein allows cancer cells to migrate and spread throughout the body, leading to poor outcomes in patients.
A new multidrug treatment combining pembrolizumab and all-trans retinoic acid has proven effective in treating stage IV melanoma, with an overall response rate of 71% and a one-year overall survival rate of 80%. The study's results are promising for patients who have failed traditional immunotherapy.
The TIL trial has demonstrated that cell therapy using patient's own immune cells is an extremely powerful immunotherapy for metastatic melanoma, with significant shrinkage of metastases in half of patients. Progression-free survival after six months was 53%, significantly better than standard immunotherapy with ipilimumab.
The study suggests a significant decrease in US melanoma mortality rates, thanks to the availability of effective therapies and new pharmacological treatments. These findings are encouraging and support the continued development of such therapies.
Researchers at the University of Pittsburgh School of Medicine have discovered a genetic link between melanoma tumors and telomere maintenance, which could lead to new treatments for the disease. The study found that mutations in the TPP1 gene stimulate telomerase activity, promoting long telomeres that enable cancer cells to divide in...
A study has identified a subset of early-stage melanoma patients with almost no risk of death, potentially contributing to overdiagnosis. The researchers used cancer registry data and developed models to identify patients with a very low risk of mortality.
A team from Massachusetts General Hospital developed an AI-based method to predict which patients with early-stage melanoma are most likely to experience a recurrence. Machine learning algorithms extracted predictive signals from clinicopathologic features, including tumor thickness and rate of cancer cell division.
A new method of modifying our immune system has been demonstrated in a study published in Advanced Science, which could help treat skin cancer.
A Phase II study found that the combination of relatlimab and nivolumab was safe and completely cleared all viable tumor in 57% of patients with stage III melanoma before surgery. The overall pathologic response rate was 70%, with no grade 3 or 4 immune-related adverse events reported.
The study analyzed DNA methylation in skin tumor samples, revealing correlations between changes in proteins regulating the organism and prognosis. The results identified potential markers of patient survival and suggested a new route for understanding melanoma subtypes.
Researchers found that high PERK activity correlates with poorer outcomes and lower anti-tumor immune cells in patients with melanoma. Inhibition of PERK promoted a type of cell death called paraptosis, which involved trafficking of immune cells to tumors and matured dendritic cells triggering anti-tumor T cell immunity.
A recent clinical trial found that patients with advanced melanoma who received immunotherapy first had a 20% higher two-year overall survival rate compared to those who initially got targeted therapies. The study also showed improved progression-free survival rates for those on immunotherapy.
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Tel Aviv University researchers discovered that skin cancer cells interact with astrocytes in the brain, promoting metastasis. By inhibiting this interaction using existing treatments, they delayed the spread of melanoma to the brain by 60-80%. This breakthrough has implications for treating advanced-stage melanoma.
Researchers found mutations in leukocyte and T-cell proliferation regulation processes that contribute to ICI treatment response and resistance. The study provides a framework to develop predictors for melanoma, potentially enhancing responses and increasing patient numbers.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.
Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
A new study by Emory University researchers suggests that antibiotics can accelerate the growth of malignant melanoma in mice by depleting their intestinal flora and weakening their immune response. This depletion leads to a higher tumor burden in infected mice compared to those with intact gut microbiomes.
Researchers from the University of Queensland are conducting a three-year project to combat melanoma, focusing on stopping its progression to the brain and investigating its seeding in a neural environment. The team aims to develop new therapies to improve treatment outcomes for affected US troops and Australians.
A recent study has found that vitamin D deficiency is associated with lower overall survival rates in melanoma patients. The research, presented at the European Academy of Dermatology and Venereology Congress, suggests that vitamin D levels play a significant role in determining patient outcomes.
Researchers discovered a small molecule Gαq/11 protein inhibitor, GQ262, that effectively combats uveal melanoma by targeting Gαq/11 directly. In vitro and in vivo studies demonstrated its ability to induce apoptosis and disrupt downstream effectors.
Researchers at Sanford Burnham Prebys have shown that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. The study identifies GCDH as the crucial enzyme in metabolizing lysine and tryptophan, amino acids essential for human health.
Researchers identified high-risk patients with stage 3A disease and microscopic lymph node metastases who would benefit from adjuvant therapy. Patients with larger metastases had poorer outcomes, while those with smaller metastases had better survival rates similar to stage 1A disease.
Researchers at the Centre for Genomic Regulation have identified PDIA6 as a key protein involved in driving melanoma malignancy. The study found that PDIA6 promotes melanoma cell growth by binding to RNA molecules inside tumor cells, making it a promising therapeutic target.
Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.
Researchers from the University of Gothenburg found that assessing melanoma thickness is challenging for both human dermatologists and machine-learning algorithms. Despite differences in success rates, both groups achieved comparable results when evaluating dermoscopic images, highlighting the need for further study to improve diagnost...
A new combination of nanoparticles and a vaccine has been developed to target melanoma. In experiments using mice, this combination eliminated cancerous tumors or extended survival rates.
Researchers uncovered details about the underlying biology of melanoma brain metastases, including genomics, immunology, and spatial organization. The study found that melanoma brain metastases are more chromosomally unstable than other types of metastases, with potential therapeutic targets in reduced chromosomal instability.
Researchers identify key features of a gene mutation responsible for 15-20% of melanomas, establishing a link between the frequency of specific NRAS mutations and spontaneous melanoma formation. The study could help pinpoint early events required for melanoma formation and develop targeted treatments.
A new combination therapy using a plant virus and an antibody activates natural killer cells to target and destroy cancer cells. The therapy eliminates all tumors and prevents their recurrence, resulting in 100% survival in mouse models of colon cancer.
Researchers found higher AR signaling and better response rates for female patients treated with BRAF/MEK inhibitors. Blocking the AR improved response to BRAF/MEK targeted therapy in both males and females.